4 results about "Troponin T" patented technology

The invention relates to the technical field of biomedicine and cardiovascular disease treatment, and discloses application of an Aralar myocardial overexpression virus in preparation of a medicine for treating heart failure. The related product is a gene therapy preparation containing an effective amount of AAV9-cTnT-Aralar, and can be matched with pharmaceutically acceptable carriers, diluents and other auxiliary materials, and the preparation is an injection type. The preparation method comprises the following steps: firstly, constructing a cardiac troponin T-carrying promoter and an AAV9 carrier of an Aralar coding nucleic acid to form a recombinant adeno-associated virus, and then matching the virus with proper auxiliary materials to prepare the preparation. The product can be used for treating heart failure accompanied with mitochondrial dysfunction, can realize heart targeted delivery and myocardial cell specific overexpression of Aralr, relieves the heart failure course by improving the myocardial cell mitochondrial function and dynamic balance, and is good in preparation stability, convenient in administration and adaptive to clinical application requirements.

The present disclosure provides gRNAs targeting the phospholamban (PLN) gene, expression cassettes, vectors, virions and compositions comprising the same, as well as methods useful for the treatment or prevention of heart disease. In some embodiments, the present disclosure provides expression cassettes and vectors comprising a polynucleotide encoding a Cas endonuclease protein operably linked to a protein expression-driving promoter (e.g., a human troponin T promoter) and / or a polynucleotide encoding a gRNA targeting a sequence of the PLN gene comprising a mutation or deletion operably linked to an RNA expression-driving promoter. The present disclosure also provides guide RNAs, expression cassettes, vectors, virions and compositions for specifically targeting PLN gene comprising a deletion of Arg14.

The myocardial cell population comprises myocardial cells obtained by differentiation of human pluripotent stem cells, and the myocardial cell population has the following characteristics: (1) cardiac troponin T positive cells account for 90% or more; (2) the spontaneous pulsation is 0 to 60 times per minute; and (3) the myocardial cell population is a cell population within 30 days from the start of differentiation. The invention also relates to a pharmaceutical composition which comprises the myocardial cell population and / or myocardial cell spheres obtained by forming the myocardial cell population into spheres, and a pharmaceutically acceptable carrier. A method of preparing the myocardial cell population comprises: (a) expanding human pluripotent stem cells; (b) culturing the expanded human pluripotent stem cells under conditions to differentiate into cardiomyocytes to produce a cell population comprising 60% or more of cardiomyocytes; and (c) removing human pluripotent stem cells and non-myocardial cells from the cell population.

The invention discloses application of a flavonoid compound or pharmaceutically acceptable salt or solvate thereof in preparation of a medicine for preventing, delaying and / or treating myocardial injury and / or heart aging. The flavonoid compound has a structure as shown in a formula (I). The flavonoid compound can increase the activity of cardiac muscle cells, inhibit the active oxygen level of the cardiac muscle cells, reduce the aging positive rate of the cardiac muscle cells, relieve neutrophil infiltration and muscle fiber breakage of cardiac muscle tissues and reduce the expression level of brain natriuretic peptide (BNP) and troponin T (cTnT) in serum. (I)